What Kawa actually did: the charges

Matthew Kawa operated two e-commerce brands simultaneously: Paradigm Peptides and Amino Asylum. Both sold synthetic peptides — including BPC-157, TB-500, IGF-1 LR3, and a range of other compounds — marketed under a “for research use only” (RUO) label, a designation that does not confer any legal authorization to sell compounds intended for human use. Federal prosecutors alleged Kawa went further than labeling violations: he distributed products tainted with undisclosed anabolic steroids, misrepresented purity and third-party testing results, and built a multi-million-dollar annual business on the back of transactions that FDA characterizes as the distribution of unapproved new drugs. Both he and Stechkober pleaded guilty on December 10, 2025, to charges in the criminal information. Sentencing was delayed to July 30, 2026, pending the full presentencing investigation. Source: DOJ USAO Northern District of Indiana (July 30, 2026).

The verdict: 70 months, a $5 million judgment, and what that means

Judge Philip Simon of the Northern District of Indiana sentenced Kawa to 70 months — just under six years — in federal prison. The court also entered a money judgment against Kawa personally in the amount of $5 million, representing the government’s estimate of proceeds derived from the criminal conduct. Both defendants were additionally ordered to pay $78,317.52 in restitution to identified victims — consumers who suffered direct documented harm. Prosecutors cited Kawa’s “knowing and deliberate” distribution of steroid-tainted products as a significant aggravating factor, alongside the scale of the operation: Amino Asylum alone was generating approximately $400,000 per month in revenue at its peak. The 70-month term substantially exceeds the 24-to-36-month range typical in FDA misdemeanor misbranding cases, reflecting the adulteration finding and the documented harm to identified consumers. Source: DOJ press release (July 30, 2026); CBS News (July 30, 2026).

Jennifer Stechkober: the co-defendant’s sentence

Stechkober, 32, who served as Kawa’s primary operational employee at Paradigm Peptides, received a 16-month prison sentence. Judge Simon found that she was “not the mastermind” of the operation — language the court used to distinguish her role from Kawa’s — but that she “played an integral role” in both the day-to-day business and in the false statements made to customers and regulators. The $78,317.52 restitution order applies jointly to both defendants. Stechkober’s sentence reflects the government’s two-tier accountability framework: the person who built the scheme and profited most receives the longest sentence; the person who carried out instructions receives a proportional but shorter term. Source: CBS News (July 30, 2026).

Paradigm Peptides and Amino Asylum: the scale of what was built

At their peaks, Paradigm Peptides and Amino Asylum were two of the largest domestic suppliers in the grey-market research peptide space. Paradigm operated primarily as a B2C storefront selling a wide range of injectable and oral peptide compounds. Amino Asylum, which Kawa operated simultaneously under a separate brand identity, catered to a bodybuilding and performance-enhancement audience and generated substantial recurring revenue before federal agents raided its operations in June 2025. The combined operation — two separate brand identities run by two family members with no FDA oversight, no compounding pharmacy license, and no prescribing relationship — is precisely what the RUO label is not supposed to enable. Federal prosecutors documented that products shipped under the Paradigm and Amino Asylum brands reached consumers in all 50 U.S. states and multiple international markets. Source: TitrateLab research archive; DOJ criminal information (Northern District of Indiana, 2025).

How this fits the broader enforcement pattern

The Kawa/Stechkober case is not an isolated outlier — it is the most recent and highest-profile data point in an enforcement pattern that has been accelerating since mid-2023. Tailor Made Compounding was prosecuted by DOJ and required to forfeit $1.79 million in addition to losing its compounding pharmacy license. Peptide Sciences, one of the largest online sources globally, closed in March 2026 with no warning to customers. In April 2026, a separate criminal case in Utah resulted in the indictment of a physician charged with prescribing misbranded peptides sourced from Chinese manufacturers to more than 200 of his own patients using a shell company. The FDA issued more than 80 warning letters to telehealth companies for misleading GLP-1 compounding claims in the trailing 12 months ending June 2026. At least seven additional research peptide companies shut down in 2025 alone, under a combination of FDA enforcement pressure, civil litigation from pharmaceutical manufacturers, and the broader tightening of the grey-market e-commerce model.

What the PCAC vote changed — and didn’t change — for vendors

The timing of the Kawa sentencing — one week after the PCAC voted to recommend BPC-157, TB-500, and four other peptides for 503A compounding — has generated confusion in some coverage. The two events are legally unrelated. The PCAC recommendation, even if it ultimately leads to a final FDA rule adding these compounds to the 503A Bulks List, does not create any legal protection for unlicensed vendors selling synthetic peptides in the interim. 503A eligibility, once granted through formal rulemaking that typically takes 12 to 24 months, authorizes licensed compounding pharmacies to prepare these compounds for specific patients with valid prescriptions. It does not authorize e-commerce retailers, and it does not retroactively cure prior violations. A vendor selling BPC-157 today under an RUO label faces identical legal exposure to what existed the day before the July 23 vote. The PCAC recommendation is a step toward a legal licensed channel; it is not a green light for the existing unlicensed one.

What researchers and the research community should understand

The Kawa case sets a sentencing benchmark that federal prosecutors in future cases can explicitly cite when requesting comparable or escalated sentences. A 70-month term and a $5 million forfeiture judgment communicate clearly that the DOJ views large-scale grey-market peptide distribution as a serious federal offense, not a technical regulatory infraction. For the research community, the practical implication is direct: any compound purchased through an unlicensed online storefront lacks chain-of-custody documentation, verified purity assurance, and the legal framework that credible research requires. The Kawa case documented that vendors operating under RUO labels may be selling adulterated products without disclosure — the steroid contamination finding is a concrete example of the quality risk the unregulated supply chain carries. The path toward legitimate access — 503A compounding through licensed pharmacies, once rulemaking concludes — is the direction regulatory activity is now pointing, but it is a 12-to-24-month horizon, not a current option.

---

Editorial Note: This article is published for research and educational purposes only. Peptide Hub does not sell peptides, receive commissions from peptide vendors, or endorse any specific supplier. All compounds discussed are research peptides not approved for human therapeutic use except where specifically noted. This is not medical advice.

Sources

1. DOJ U.S. Attorney’s Office, Northern District of Indiana — Illinois man and Indiana woman sentenced: justice.gov
2. DOJ — United States v. Matthew Kawa case page: justice.gov
3. CBS News — Judge sentences peptide vendor to nearly 6 years in prison: cbsnews.com
4. NewsDive — E-commerce peptide vendor receives nearly six-year prison term: newsdive.net
5. TitrateLab — Paradigm Peptides / Amino Asylum plea and sentencing archive: titratelab.com